An Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Icalcaprant in Healthy Adult Japanese and Han Chinese Subjects
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Icalcaprant (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions; Pharmacokinetics
- Acronyms 528 Asian PK
- Sponsors AbbVie
- 28 Jan 2025 Status changed from active, no longer recruiting to completed.
- 27 Dec 2024 Status changed from recruiting to active, no longer recruiting.
- 12 Dec 2024 New trial record